[
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Stock Moves -1.18%: What You Should Know",
    "summary": "Gilead Sciences (GILD) concluded the recent trading session at $105.93, signifying a -1.18% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=013cd4fe086a47003b2211774304cb9dfe0c9a9c29566261a7595792c2bed185",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750888803,
      "headline": "Gilead Sciences (GILD) Stock Moves -1.18%: What You Should Know",
      "id": 135535278,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (GILD) concluded the recent trading session at $105.93, signifying a -1.18% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=013cd4fe086a47003b2211774304cb9dfe0c9a9c29566261a7595792c2bed185"
    }
  },
  {
    "ts": null,
    "headline": "Alger Russell Innovation Index Updates for Second Quarter 2025",
    "summary": "Fred Alger Management, LLC (\"Alger\"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index (\"Index\"). Following the close of trading on Friday, June 27, 2025, the Index will be rebalanced, and the following changes will be effective.",
    "url": "https://finnhub.io/api/news?id=106da9ac92f6d0b0b0da41b004b657f1f12597aeb761b26ec09a3a53cb1633f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750878540,
      "headline": "Alger Russell Innovation Index Updates for Second Quarter 2025",
      "id": 135527916,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Fred Alger Management, LLC (\"Alger\"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index (\"Index\"). Following the close of trading on Friday, June 27, 2025, the Index will be rebalanced, and the following changes will be effective.",
      "url": "https://finnhub.io/api/news?id=106da9ac92f6d0b0b0da41b004b657f1f12597aeb761b26ec09a3a53cb1633f9"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (NasdaqGS:GILD) Partners With Kymera In US$750 Million Cancer Treatment Deal",
    "summary": "Gilead Sciences (NasdaqGS:GILD) recently entered an exclusive agreement with Kymera Therapeutics to advance a molecular glue degrader program targeting CDK2, enhancing its oncology pipeline. Additionally, the FDA approved Yeztugo as a breakthrough HIV prevention option. Both events underscore Gilead's strength in innovation. Despite these developments, Gilead's share price remained flat over the past month, contrasting with the broader market's 1.9% rise in seven days. While these initiatives...",
    "url": "https://finnhub.io/api/news?id=90081c993a9d4af62b80e88f56b92c4329d403fa6c99778b60b98cb2fa111bdd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750872525,
      "headline": "Gilead Sciences (NasdaqGS:GILD) Partners With Kymera In US$750 Million Cancer Treatment Deal",
      "id": 135527917,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (NasdaqGS:GILD) recently entered an exclusive agreement with Kymera Therapeutics to advance a molecular glue degrader program targeting CDK2, enhancing its oncology pipeline. Additionally, the FDA approved Yeztugo as a breakthrough HIV prevention option. Both events underscore Gilead's strength in innovation. Despite these developments, Gilead's share price remained flat over the past month, contrasting with the broader market's 1.9% rise in seven days. While these initiatives...",
      "url": "https://finnhub.io/api/news?id=90081c993a9d4af62b80e88f56b92c4329d403fa6c99778b60b98cb2fa111bdd"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves Gilead’s twice-yearly injectable Yeztugo for PrEP",
    "summary": "Yetzugo is a long-acting HIV-1 capsid inhibitor that reduces the risk of sexually acquired HIV in adults and adolescents.",
    "url": "https://finnhub.io/api/news?id=6167582985a44f87cb0fc1798978485298669a02777f1a3c272d84fbc0affe78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750871706,
      "headline": "FDA approves Gilead’s twice-yearly injectable Yeztugo for PrEP",
      "id": 135527918,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Yetzugo is a long-acting HIV-1 capsid inhibitor that reduces the risk of sexually acquired HIV in adults and adolescents.",
      "url": "https://finnhub.io/api/news?id=6167582985a44f87cb0fc1798978485298669a02777f1a3c272d84fbc0affe78"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=4ec0f5ff5d39e92238b640004e1f40b56c03f0cab014fb865239a5ee371e28b7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750869360,
      "headline": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
      "id": 135542677,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=4ec0f5ff5d39e92238b640004e1f40b56c03f0cab014fb865239a5ee371e28b7"
    }
  },
  {
    "ts": null,
    "headline": "Kymera Shrugs Off Sanofi Bust With Gilead Deal--But There Are Caveats",
    "summary": "Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers hope. Click for my GILD and KYMR update.",
    "url": "https://finnhub.io/api/news?id=810ae2f34df725691049ba57fc578b945bc215c7d608a9beef8e086dd498a6b0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750856961,
      "headline": "Kymera Shrugs Off Sanofi Bust With Gilead Deal--But There Are Caveats",
      "id": 135526979,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177771720/image_2177771720.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers hope. Click for my GILD and KYMR update.",
      "url": "https://finnhub.io/api/news?id=810ae2f34df725691049ba57fc578b945bc215c7d608a9beef8e086dd498a6b0"
    }
  },
  {
    "ts": null,
    "headline": "Kymera adds Gilead as research partner, while advancing new candidate with Sanofi",
    "summary": "The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a new drug prospect, meanwhile.",
    "url": "https://finnhub.io/api/news?id=a6616c1aad2e7bf1e439208fa2013ea20df8081a49a4d5eaa9af6ae189581a06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750853220,
      "headline": "Kymera adds Gilead as research partner, while advancing new candidate with Sanofi",
      "id": 135527919,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a new drug prospect, meanwhile.",
      "url": "https://finnhub.io/api/news?id=a6616c1aad2e7bf1e439208fa2013ea20df8081a49a4d5eaa9af6ae189581a06"
    }
  },
  {
    "ts": null,
    "headline": "Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B",
    "summary": "– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of 3.2 logs IU/mL over 28 days of treatment for 400 mg cohort consistent with findings in 150 mg cohort, supporting ability of 150 mg dose to achieve saturated inhibition of viral replication, as anticipated – – Trial completion triggers opt-in point under collaboration with Gilead Sciences, Inc. following d",
    "url": "https://finnhub.io/api/news?id=7e1dc6c57e93c1dc5e31d29eaff2517ac1390241d0829c6e81dea88d6bedcb78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750852800,
      "headline": "Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B",
      "id": 135527920,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of 3.2 logs IU/mL over 28 days of treatment for 400 mg cohort consistent with findings in 150 mg cohort, supporting ability of 150 mg dose to achieve saturated inhibition of viral replication, as anticipated – – Trial completion triggers opt-in point under collaboration with Gilead Sciences, Inc. following d",
      "url": "https://finnhub.io/api/news?id=7e1dc6c57e93c1dc5e31d29eaff2517ac1390241d0829c6e81dea88d6bedcb78"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders",
    "summary": "FOSTER CITY, Calif. & WATERTOWN, Mass., June 25, 2025--Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential including in breast cancer and other solid tumors.",
    "url": "https://finnhub.io/api/news?id=870ede98ad984ec8a5749b8348b2aff1078cd0a7dd52d3d9d6a87edf4766e996",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750849200,
      "headline": "Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders",
      "id": 135527921,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif. & WATERTOWN, Mass., June 25, 2025--Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential including in breast cancer and other solid tumors.",
      "url": "https://finnhub.io/api/news?id=870ede98ad984ec8a5749b8348b2aff1078cd0a7dd52d3d9d6a87edf4766e996"
    }
  },
  {
    "ts": null,
    "headline": "Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics",
    "summary": "Gilead Sciences has enteredinto an option and license deal with Kymera Therapeuticsto support the development and sales of a class ofcancer drugs, the companies said on Wednesday. As...",
    "url": "https://finnhub.io/api/news?id=89a2ef038bebbcb31c3a640a6e0a4b063e8269c8471a66139fbbfe138d027f9f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750842211,
      "headline": "Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics",
      "id": 135524805,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Gilead Sciences has enteredinto an option and license deal with Kymera Therapeuticsto support the development and sales of a class ofcancer drugs, the companies said on Wednesday. As...",
      "url": "https://finnhub.io/api/news?id=89a2ef038bebbcb31c3a640a6e0a4b063e8269c8471a66139fbbfe138d027f9f"
    }
  },
  {
    "ts": null,
    "headline": "My Dividend Stock Portfolio: New May Dividend Record - 100 Holdings With 15 Buys",
    "summary": "Explore May 2025 market volatility, U.S.-China trade talks, and record dividend income growth.",
    "url": "https://finnhub.io/api/news?id=28d3b832c1fca31770119594903f09760ded636b8898fcc7533e46ddeeaa3cac",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750839000,
      "headline": "My Dividend Stock Portfolio: New May Dividend Record - 100 Holdings With 15 Buys",
      "id": 135524419,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Explore May 2025 market volatility, U.S.-China trade talks, and record dividend income growth.",
      "url": "https://finnhub.io/api/news?id=28d3b832c1fca31770119594903f09760ded636b8898fcc7533e46ddeeaa3cac"
    }
  },
  {
    "ts": null,
    "headline": "AMG Boston Common Global Impact Fund Q1 2025 Commentary",
    "summary": "The AMG Boston Common Global Impact Fund returned -3.81% for the first quarter of 2025, compared with -1.33% for the benchmark, the MSCI ACWI Index.",
    "url": "https://finnhub.io/api/news?id=28969ec43a78beaef1cdae3b06a370e84a470c3b1bad6fb2885521542aac4a64",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750838400,
      "headline": "AMG Boston Common Global Impact Fund Q1 2025 Commentary",
      "id": 135524348,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1613300198/image_1613300198.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "The AMG Boston Common Global Impact Fund returned -3.81% for the first quarter of 2025, compared with -1.33% for the benchmark, the MSCI ACWI Index.",
      "url": "https://finnhub.io/api/news?id=28969ec43a78beaef1cdae3b06a370e84a470c3b1bad6fb2885521542aac4a64"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Kymera Therapeutics Set Cancer-Drug Collaboration",
    "summary": "By Colin Kellaher Gilead Sciences and Kymera Therapeutics have inked an exclusive cancer-drug option and licensing agreement potentially worth hundreds of million of dollars to Kymera. The...",
    "url": "https://finnhub.io/api/news?id=42affa3c45754139d8f40869c6391ee1b9a133ff38b054a2d73a57fb2b929341",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750837629,
      "headline": "Gilead Sciences, Kymera Therapeutics Set Cancer-Drug Collaboration",
      "id": 135524137,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Gilead Sciences and Kymera Therapeutics have inked an exclusive cancer-drug option and licensing agreement potentially worth hundreds of million of dollars to Kymera. The...",
      "url": "https://finnhub.io/api/news?id=42affa3c45754139d8f40869c6391ee1b9a133ff38b054a2d73a57fb2b929341"
    }
  }
]